The Blue Cross NC Medical Oncology Program promotes optimal support for our members' cancer care needs, while reducing the costs for managing one of the most complex, expensive and prevalent diseases they can encounter. (Effective April 1, 2017)
This program includes online access to support tools for selecting cancer treatment regimens, consistent with current evidence and consensus guidelines for oncologists and hematologists. The program includes Carelon Cancer Treatment Pathways (Pathways) based on medical evidence and best practices developed with leading cancer experts.
Pathway regimens are widely accepted as a key component to managing oncology quality and cost. Carelon Cancer Treatment Pathways offer support in identifying highly effective therapies that are often more affordable for our members. More specific than guidelines, they identify treatments based on clinical efficacy, favorable toxicity profiles and cost.
Pathway regimens in this program are informed by a clinical library and include evidence drawn from:
- Peer-reviewed published literature
- Expert consensus statements and guidelines from professional organizations, including:
- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- National Comprehensive Cancer Network (NCCN)
- Federal government agencies, including:
- Food and Drug Administration (FDA)
- National Cancer Institute (NCI)